An unknown reaction to pembrolizumab: giant cell arteritis

被引：35
作者：
Micaily, I. [1 ]
Chernoff, M. [2 ]
机构：
[1] Abington Jefferson Hlth, Dept Med, Abington, PA 19001 USA
[2] Abington Jefferson Hlth, Abington Hematol Oncol Associates, Abington, PA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷 / 10期
关键词：
IMMUNE CHECKPOINT INHIBITORS;
D O I：
10.1093/annonc/mdx306
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2621 / 2622
页数：2
相关论文
共 4 条
  • [1] Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
    Friedman, Claire F.
    Proverbs-Singh, Tracy A.
    Postow, Michael A.
    [J]. JAMA ONCOLOGY, 2016, 2 (10) : 1346 - 1353
  • [2] Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis
    Nishijima, Tomohiro F.
    Shachar, Shlomit S.
    Nyrop, Kirsten A.
    Muss, Hyman B.
    [J]. ONCOLOGIST, 2017, 22 (04) : 470 - 479
  • [3] Postow Michael A, 2015, Am Soc Clin Oncol Educ Book, P76, DOI 10.14694/EdBook_AM.2015.35.76
  • [4] Management of toxicities of immune checkpoint inhibitors
    Spain, Lavinia
    Diem, Stefan
    Larkin, James
    [J]. CANCER TREATMENT REVIEWS, 2016, 44 : 51 - 60
1